Evidence map›Paper›PMID 39725615›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2024

[

Lihua Yu, Jingya Li, Xiaoqi Wang, Li Li, Ya Chen, Feiyu Wang, Kun Zhang, Tongsheng Wang

Abstract readEnglish Abstract
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Journal of inflammation research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lihua YuDepartment of Physiology and Pharmacology, School of Integrated Chinese and Western Medicine, Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine, Taihe 236600, China.
Jingya LiDepartment of Physiology and Pharmacology, School of Integrated Chinese and Western Medicine, Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine, Taihe 236600, China.
Xiaoqi WangSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China, Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine, Taihe 236600, China.
Li LiDepartment of Physiology and Pharmacology, School of Integrated Chinese and Western Medicine, Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine, Taihe 236600, China.
Ya ChenDepartment of Nephrology, Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine, Taihe 236600, China.
Feiyu WangSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China, Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine, Taihe 236600, China.
Kun ZhangSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China, Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine, Taihe 236600, China.
Tongsheng WangDepartment of Physiology and Pharmacology, School of Integrated Chinese and Western Medicine, Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine, Taihe 236600, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the inhibitory effect of Danshen Injection on endothelial-mesenchymal transition (EndMT) induced by peritoneal dialysis fluid in HMrSV5 cells and the role of the TGF‑β/Smad signaling pathway in mediating this effect.

methodsHMrSV5 cells cultured in 40% peritoneal dialysis solution for 72 h to induce EndMT were treated with 0.05%, 0.1% and 0.5% Danshen Injection. CCK-8 assay was used to assess the changes in viability of the treated cells, and the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β), and vascular endothelial growth factor (VEGF) in the cell supernatant were detected using ELISA; Western blotting was performed to detect the protein expressions of E-cadherin, α-smooth muscle actin (α-SMA), p-Smad 2/3, and Smad 7 in the cells.

resultsCulture in 40% peritoneal dialysis fluid for 72 induced significant EndMT in HMrSV5 cells, which exhibited obviously lowered cell viability. Danshen Injection within the concentration range of 0.025%-1.5% did not significantly affect the viability of the cells. Exposure of HMrSV5 cells to peritoneal dialysis fluid for 72 h significantly increased the production of IL-6, TNF‑α, TGF‑β and VEGF, upregulated the protein expressions of α‑SMA and p-Smad 2/3, and lowered the expressions of E-cadherin and Smad7 proteins. Treatment of the exposed cells with Danshen injection significantly increased cell viability and cellular expressions of E-cadherin and Smad 7 proteins and reduced the production of IL-6, TNF-α, TGF-β and VEGF and the protein expressions of α‑SMA and p-Smad 2/3.

conclusionsDanshen Injection can suppress peritoneal dialysis fluid-induced EndMT in HMrSV5 cells possibly by regulating the TGF-β/Smad signaling pathway.

Indexed as

Drugs, Chinese HerbalEpithelial-Mesenchymal TransitionPeritoneal DialysisSalvia miltiorrhizaSignal TransductionSmad ProteinsTransforming Growth Factor betaVascular Endothelial Growth Factor AActinsCadherinsCell LineDialysis SolutionsEndothelial-Mesenchymal TransitionHumansInterleukin-6Tumor Necrosis Factor-alphaActinsCadherinsdan-shen root extractDialysis SolutionsDrugs, Chinese HerbalInterleukin-6Smad ProteinsTransforming Growth Factor betaTumor Necrosis Factor-alphaVascular Endothelial Growth Factor ADanshen Injectionendothelial-mesenchymal transitionperitoneal dialysateperitoneal fibrosisTGF‑β/Smad signaling pathway

Identifiers

PMID39725615
PMCPMC11683338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.